Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

New Drug Combo Could Prevent Head and Neck Cancer in High-Risk Patients

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
A new combination of drugs has demonstrated potential in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck.

“Squamous cell carcinoma of the head and neck [SCCHN] is the most common type of head and neck cancer,” said Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology at Emory University School of Medicine (Atlanta, GA, USA), and director of the Cancer Chemoprevention Program at Winship Cancer Institute at Emory University. “The survival rate for patients with SCCHN is very poor. An effective prevention approach is desperately needed, especially since we can identify patients who are at extremely high risk: those with advanced oral precancerous lesions.”

Based on earlier research suggesting a role for epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in promoting SCCHN, Dr. Shin and colleagues believed combining an EGFR inhibitor and a COX-2 inhibitor could provide an effective chemopreventive approach. They found that the combination of the EGFR inhibitor erlotinib and the COX-2 inhibitor celecoxib was more effective for inhibiting the growth of human SCCHN cell lines compared with either drug alone. Moreover, treating mice with the drug combination prior to transplanting them with human SCCHN cells more effectively suppressed cancer cell growth than did pretreating the mice with either drug alone.

Dr. Shin and colleagues, based on these preclinical analyses, initiated a phase I chemoprevention trial. Eleven patients with advanced oral precancerous lesions were assigned to treatment with erlotinib and celecoxib. Tissue samples from the patients were taken and assessed pathologically at 3, 6, and 12 months after the start of therapy. Biopsies at baseline and follow-up were available for seven patients. The study’s findings, which included preclinical and clinical analyses, were published February 2013 in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Pathologic examination of the biopsies indicated that three of the seven patients had a complete pathologic response; that is, there was no longer evidence of the precancerous lesions in the follow-up biopsy sample. Among the other patients, two had a partial pathologic response and two had progressive disease. “Finding that this drug combination caused some advanced premalignant lesions to completely disappear was great news,” remarked Dr. Shin. “Advanced premalignant lesions rarely regress, so our data are proof-of-principle that a combination chemopreventive strategy with molecularly targeted agents is possible.”

Several patients dropped out of the trial because of severe adverse side effects, according to Dr. Shin. “Prevention is not achieved through short-term treatment,” he said. “So, we need to investigate the safety and toxicity of this combination further before planning a large-scale trial. We are also looking to combination therapies using less toxic or nontoxic agents, such as natural compounds.”

Related Links:

Emory University School of Medicine



view channel
Image: representation of a protein (blue), which contains three zinc fingers in complex with DNA (orange). The coordinating amino acid residues and zinc ions (green) are highlighted (Photo courtesy of Wikimedia Commons).

Molecular Sensors Generated by Synthetic Biology Technique Using Intein-Based Protein Splicing

Biotech researchers have used intein-based protein splicing to generate synthetic protein components that are able to detect specific DNA sequences and subsequently trigger a desired intracellular response... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.